1,403.80
-0.51%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Cipla Ltd
Its shares trade on NSE under the ticker CIPLA.NS. It has been listed since 3 November 1994. It is a member of the Nifty 50. In the fiscal year to 31 March 2026, it reported revenue of ₹281.63bn and net income of ₹38.79bn. At that date it held total assets of ₹424.96bn and shareholders' equity of ₹344.32bn.
Cipla Ltd. engages in the manufacture and distribution of healthcare products and bulk drugs. The company is headquartered in Mumbai, Maharashtra. The Company’s segments include Pharmaceuticals and New ventures. The Pharmaceuticals segment is engaged in developing, manufacturing, selling and distributing generic or branded generic medicines, as well as Active Pharmaceutical Ingredients (API). The New ventures segment includes the operations of the Company, a consumer healthcare, Biosimilars and specialty business. Its product portfolio spans complex generics, as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective and central nervous system (CNS). The firm's geographical segments include India, the United States, South Africa and Rest of the World. The firm has its network of manufacturing, trading and other incidental operations in India and International markets. The firm has approximately 46 manufacturing sites.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 3 Nov 1994
- Employees
- 21,891
- Website
- cipla.com ↗
Leadership
Pay as last reported
- Dr. Yusuf HamiedNon-Executive Chairman of the Board, since 1976₹26.1m
- Mr. Umang VohraGlobal Chief Executive Officer, Managing Director, Executive Director₹160.0m
- Mr. Ashish AdukiaGlobal Chief Financial Officer
- Mr. Achin GuptaGlobal Chief Operating Officer
- Ms. Sneha HiranandaniChief Information Officer
- Mr. Rajendra ChopraCompliance Officer, Company Secretary₹15.3m
- Mr. Rajeev SinhaGlobal Chief Manufacturing Officer
- Mr. Kamil HamiedNon-Executive Director
- Mr. Abhijit JoshiAdditional Non-Executive Director
- Mr. Adil ZainulbhaiAdditional Non-Executive Director₹10.1m
- Ms. Maya HariAdditional Independent Director
- Dr. Balram BhargavaIndependent Non-Executive Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 84
- Environment
- 71
- Social
- 91
- Governance
- 89
- Direct emissions (scope 1)
- 778,218 t
- Energy emissions (scope 2)
- 129,087 t
- Value chain emissions (scope 3)
- 5,028,316 t
- Women in the workforce
- 15.87%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Cipla Ltd has a strong reputation in the pharmaceutical industry with a diverse product portfolio and a presence in over 170 countries. The company has a robust research and development department, enabling innovation and the development of new drugs. Cipla also has a strong distribution network and brand recognition, allowing it to reach a wide customer base.
- Furthermore, Cipla's focus on cost-effective manufacturing processes and its ability to offer affordable medicines give it a competitive advantage in emerging markets.
Weaknesses
- One of Cipla's weaknesses is its strong dependence on the Indian pharmaceutical market, which contributes a significant portion of its revenue. Any changes in regulations or market conditions in India can impact the company's financial performance.
- Additionally, Cipla faces challenges in terms of maintaining its product quality and overcoming regulatory compliance issues in certain markets.
Opportunities
- The global pharmaceutical market is expected to grow in the coming years, presenting opportunities for Cipla to expand its presence and market share. The increasing demand for generic drugs, especially in emerging markets, provides great potential for Cipla's cost-effective manufacturing capabilities.
- Cipla can also explore strategic collaborations and partnerships to enhance its research and development capabilities and tap into new markets.
Threats
- The pharmaceutical industry is highly competitive, and Cipla faces threats from other established players as well as new entrants. Changes in government regulations, intellectual property rights, and pricing pressures can also impact Cipla's profitability.
- Moreover, the ongoing COVID-19 pandemic presents uncertainties and challenges for Cipla's global operations.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.